Objective: To examine the association between CYP1A1 polymorphisms (MspI and Ile/Val) and esophageal cancer (EC) by systematically reviewing the risk of the original studies.
Methods: Data from 16 papers (8 for MspI, 14 for Ile/Val) regarding case-control studies on the association of cytochrome P450 polymorphisms and risk of esophageal cancer was analyzed by dominant model (variant genotype vs. wild-type genotype) through meta-analysis. Stratified analysis was carried out according to the pathological types.
Results: In systematical analysis, CYP1A1 MspI variant genotype (TC + CC) had no association with EC risk (OR = 1.17, 95%CI: 0.82 - 1.66). Similar results were observed in esophageal squamous-cell carcinoma (ESCC) (OR = 1.17, 95%CI: 0.82 - 1.69) and esophageal adenocarcinoma (EAC) (OR = 1.39, 95%CI: 0.67 - 2.09). Individuals with the CYP1A1 Ile/Val variant genotype (Ile/Val + Val/Val) had an increased risk for EC, when comparing with wild type (Ile/Ile), with an OR of 1.39 (95%CI: 1.07 - 1.80). CYP1A1 Ile/Val variant genotype could increase the risk of ESCC (OR = 1.43, 95%CI: 1.07 - 1.91) but no significant association was found with EAC (OR = 1.20, 95%CI: 0.62 - 2.30).
Conclusion: CYP1A1 gene polymorphism Ile/Val might have played a role in the development of ESCC but CYP1A1 MspI polymorphism might not be associated with the susceptibility of EC.